Virtu Financial LLC Invests $382,000 in Adaptive Biotechnologies Co. (NASDAQ:ADPT)


Share on StockTwits

Virtu Financial LLC purchased a new position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,461 shares of the company’s stock, valued at approximately $382,000.

Several other large investors have also added to or reduced their stakes in the company. Bank Julius Baer & Co. Ltd Zurich grew its stake in shares of Adaptive Biotechnologies by 102.1% in the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 111,940 shares of the company’s stock worth $6,619,000 after purchasing an additional 56,545 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of Adaptive Biotechnologies by 2.0% in the fourth quarter. Principal Financial Group Inc. now owns 323,287 shares of the company’s stock worth $19,115,000 after purchasing an additional 6,213 shares in the last quarter. Truist Financial Corp bought a new position in shares of Adaptive Biotechnologies in the fourth quarter worth $273,000. Voloridge Investment Management LLC boosted its stake in Adaptive Biotechnologies by 124.5% during the fourth quarter. Voloridge Investment Management LLC now owns 223,339 shares of the company’s stock valued at $13,206,000 after buying an additional 123,836 shares in the last quarter. Finally, Adalta Capital Management LLC bought a new position in Adaptive Biotechnologies during the fourth quarter valued at about $207,000. 80.80% of the stock is owned by institutional investors.

Shares of NASDAQ ADPT opened at $40.63 on Thursday. Adaptive Biotechnologies Co. has a 12 month low of $23.68 and a 12 month high of $71.25. The company has a market cap of $5.66 billion, a price-to-earnings ratio of -42.77 and a beta of 0.35. The business has a fifty day simple moving average of $46.63 and a 200-day simple moving average of $52.54.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Tuesday, February 23rd. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.04). The business had revenue of $30.19 million during the quarter, compared to analysts’ expectations of $27.08 million. Adaptive Biotechnologies had a negative return on equity of 20.15% and a negative net margin of 132.32%. Research analysts anticipate that Adaptive Biotechnologies Co. will post -1.08 earnings per share for the current fiscal year.

In other Adaptive Biotechnologies news, President Julie Rubinstein sold 8,814 shares of the company’s stock in a transaction dated Friday, January 8th. The stock was sold at an average price of $60.46, for a total value of $532,894.44. Following the transaction, the president now directly owns 15,000 shares of the company’s stock, valued at approximately $906,900. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Sharon Benzeno sold 417 shares of the company’s stock in a transaction dated Tuesday, January 19th. The stock was sold at an average price of $69.00, for a total value of $28,773.00. Following the completion of the transaction, the insider now directly owns 417 shares in the company, valued at $28,773. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,264,609 shares of company stock valued at $65,272,781. Company insiders own 22.20% of the company’s stock.

ADPT has been the subject of several research reports. BTIG Research raised their target price on Adaptive Biotechnologies from $66.00 to $74.00 and gave the company a “buy” rating in a research note on Tuesday, January 19th. Morgan Stanley raised their target price on Adaptive Biotechnologies from $46.00 to $60.00 and gave the company an “equal weight” rating in a research note on Thursday, March 4th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $63.00 target price (down previously from $74.00) on shares of Adaptive Biotechnologies in a research note on Tuesday, March 9th. Finally, Zacks Investment Research cut Adaptive Biotechnologies from a “hold” rating to a “sell” rating in a research note on Tuesday, January 12th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $59.33.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection.

Recommended Story: What is a front-end load?

Want to see what other hedge funds are holding ADPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adaptive Biotechnologies Co. (NASDAQ:ADPT).

Institutional Ownership by Quarter for Adaptive Biotechnologies (NASDAQ:ADPT)

Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.